Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 16/20 | 0.43 |
| ▸ | CDK4 | P11802 | 14/20 | 0.43 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.40 |
| ▸ | CCND3 | P30281 | 4/20 | 0.39 |
| ▸ | CCND2 | P30279 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22171354 | 0.89 | CDK4 (0.49) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL29593638 | 0.84 | CCND1 (0.43) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL4830675 | 0.84 | CCND1 (0.43) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL25045064 | 0.83 | CCND1 (0.42) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL4833014 | 0.82 | CCND1 (0.56) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL4835890 | 0.80 | CCND1 (0.56) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL21564387 | 0.78 | CDK4 (0.65) | CCND1CDK4CDK2CCNA2CCND3 | |
| SCHEMBL29779676 | 0.78 | CDK4 (0.65) | CCND1CDK4CDK2CCNA2CCND3 | |
| SCHEMBL5900355 | 0.78 | CCND1 (0.45) | CCND1CDK4CDK2FGFR1CCNA2 | |
| SCHEMBL5900383 | 0.78 | CDK2 (0.59) | CCND1CDK4CDK2FGFR1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CCND1 51/4885CDK4 9/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.